Page 1916 - Williams Hematology ( PDFDrive )

1890 Part XII: Hemostasis and Thrombosis Chapter 112: Platelet Morphology, Biochemistry, and Function 1891

326. Coppinger JA, et al: Characterization of the proteins released from activated platelets 360. Capitanio AM, et al: Interaction of platelet factor 4 with human platelets. Biochim
leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood Biophys Acta 839(2):161–173, 1985.
103(6):2096–2104, 2004. 361. Dumenco LL, et al: Inhibition of the activation of Hageman factor (factor XII) by
327. Maynard DM, et al: Proteomic analysis of platelet alpha-granules using mass spec- platelet factor 4. J Lab Clin Med 112(3):394–400, 1988.
trometry. J Thromb Haemost 5(9):1945–1955, 2007. 362. Aziz KA, Cawley JC, Zuzel M: Platelets prime PMN via released PF4: Mechanism of
328. McRedmond JP, et al: Integration of proteomics and genomics in platelets: A profile of priming and synergy with GM-CSF. Br J Haematol 91(4):846–853, 1995.
platelet proteins and platelet-specific genes. Mol Cell Proteomics 3(2):133–144, 2004. 363. Engstad CS, et al: A novel biological effect of platelet factor 4 (PF4): Enhancement of
329. Italiano JE Jr, Richardson JL, Patel-Hett S, et al: Angiogenesis is regulated by a novel LPS-induced tissue factor activity in monocytes. J Leukoc Biol 58(5):575–581, 1995.
mechanism: Pro- and antiangiogenic proteins are organized into separate platelet 364. Castor CW, Miller JW, Walz DA: Structural and biological characteristics of connec-
alpha granules and differentially released. Blood 111(3):1227–1233, 2008. tive tissue activating peptide (CTAP-III), a major human platelet-derived growth fac-
330. Sehgal S, Storrie B: Evidence that differential packaging of the major platelet granule tor. Proc Natl Acad Sci U S A 80(3):765–769, 1983.
proteins von Willebrand factor and fibrinogen can support their differential release. J 365. Holt JC, et al: Characterization of human platelet basic protein, a precursor form
Thromb Haemost 5(10):2009–2016, 2007. of low-affinity platelet factor 4 and beta-thromboglobulin. Biochemistry 25(8):
331. George JN: Platelet immunoglobulin G: Its significance for the evaluation of throm- 1988–1996, 1986.
bocytopenia and for understanding the origin of alpha-granule proteins. Blood 366. Walz A, et al: Effects of the neutrophil-activating peptide NAP-2, platelet basic pro-
76(5):859–870, 1990. tein, connective tissue-activating peptide III and platelet factor 4 on human neu-
332. George JN, Platelet IgG: Measurement, interpretation, and clinical significance. Prog trophils. J Exp Med 170(5):1745–1750, 1989.
Hemost Thromb 10:97–126, 1991. 367. Bastl CP, et al: Role of kidney in the catabolic clearance of human platelet antiheparin
333. Heijnen HF, et al: Multivesicular bodies are an intermediate stage in the formation of proteins from rat circulation. Blood 57(2):233–238, 1981.
platelet alpha-granules. Blood 91(7):2313–2325, 1998. 368. Hayward CP: Multimerin: A bench-to-bedside chronology of a unique platelet and
334. Niewiarowski S: Secreted platelet proteins, in Haemostasis and Thrombosis, edited by endothelial cell protein—from discovery to function to abnormalities in disease. Clin
AL Bloom, DP Thomas, EGD Tuddenham, p 167. Churchill Livingstone, London, Invest Med 20(3):176–187, 1997.
England, 1994. 369. Polgar J, et al: Platelet glycoprotein Ia* is the processed form of multimerin—isolation
335. Niewiarowski S, Holt JC, Cook JJ: Biochemistry and physiology of secreted platelet and determination of N-terminal sequences of stored and released forms. Thromb
proteins, in Hemostasis and Thrombosis: Basic Principles and Clinical Practice, edited Haemost 80(4):645–648, 1998.
by RW Colman, VJ Marder, EW Salzman, p 546. JB Lippincott, Philadelphia, 1993. 370. Hayward CP, et al: Studies of multimerin in human endothelial cells. Blood
336. Brown KD, et al: A family of small inducible proteins secreted by leukocytes are mem- 91(4):1304–1317, 1998.
bers of a new superfamily that includes leukocyte and fibroblast-derived inflamma- 371. Harrison P: Platelet alpha-granular fibrinogen. Platelets 3(1):1–10, 1992.
tory agents, growth factors, and indicators of various activation processes. J Immunol 372. Harrison P, Wilbourn BR, Saundry RH, et al: Absence of the γ-Leu 427 (γ′) variant in the
142(2):679–687, 1989. platelet alpha-granular fibrinogen pool supports the role of glycoprotein IIb/IIIa in medi-
337. Kawahara RS, Deuel TF: Platelet-derived growth factor-inducible gene JE is a member ating fibrinogen uptake into platelets/megakaryocytes. Blood 79(12):3394–3395, 1992.
of a family of small inducible genes related to platelet factor 4. J Biol Chem 264(2): 373. Reheman A, et al: Plasma fibronectin depletion enhances platelet aggregation and
679–682, 1989. thrombus formation in mice lacking fibrinogen and von Willebrand factor. Blood
338. Oppenheim JJ, et al: Properties of the novel proinflammatory supergene “intercrine” 2009;113(8):1809–1817, 1992.
cytokine family. Annu Rev Immunol 9:617–648, 1991. 374. Cho J, Mosher DF: Role of fibronectin assembly in platelet thrombus formation. J
339. Gear AR, Camerini D: Platelet chemokines and chemokine receptors: Linking hemo- Thromb Haemost 4(7):1461–1469, 2006.
stasis, inflammation, and host defense. Microcirculation 10(3–4):335–350, 2003. 375. Coller BS, et al: Platelet fibrinogen and vitronectin in Glanzmann thrombasthenia:
340. Rollins BJ: Chemokines. Blood 90(3):909–928, 1997. Evidence consistent with specific roles for glycoprotein IIb/IIIA and alpha v beta 3
341. Handin RI, Cohen HJ: Purification and binding properties of human platelet factor integrins in platelet protein trafficking. Blood 78(10):2603–2610, 1991.
four. J Biol Chem 251(14):4273–4282, 1976. 376. Eitzman DT, et al: Plasminogen activator inhibitor-1 and vitronectin promote vascu-
342. Loscalzo J, Melnick B, Handin RI: The interaction of platelet factor four and gly- lar thrombosis in mice. Blood 95(2):577–580, 2000.
cosaminoglycans. Arch Biochem Biophys 240(1):446–455, 1985. 377. Fay WP, et al: Vitronectin inhibits the thrombotic response to arterial injury in mice.
343. Rucinski B, et al: Human platelet factor 4 and its C-terminal peptides: Heparin bind- Blood 93(6):1825–1830, 1999.
ing and clearance from the circulation. Thromb Haemost 63(3):493–498, 1990. 378. Konstantinides S, et al: Plasminogen activator inhibitor-1 and its cofactor vitronectin
344. Barber AJ, Käser-Glanzmann R, Jakábová M, Lüscher EF: Chromatography of chon- stabilize arterial thrombi after vascular injury in mice. Circulation 103(4):576–583,
droitin sulfate proteoglycan carrier for heparin neutralizing activity (platelet factor 4) 2001.
released from human blood platelets. Biochim Biophys Acta 286. 379. Adams JC, Lawler J, The thrombospondins. Int J Biochem Cell Biol 36(6):961–968,
345. Huang SS, Huang JS, Deuel TF: Proteoglycan carrier of human platelet factor 4. Isola- 2004.
tion and characterization. J Biol Chem 1982;257(19):11546–11550, 1972. 380. Baenziger NL, Brodie GN, Majerus PW: A thrombin-sensitive protein of human
346. Busch C, et al: Binding of platelet factor 4 to cultured human umbilical vein endothe- platelet membranes. Proc Natl Acad Sci U S A 68(1):240–243, 1971.
lial cells. Thromb Res 19(1–2):129–137, 1980. 381. Lawler J, Hynes RO: The structure of human thrombospondin, an adhesive glyco-
347. Clore GM, Gronenborn AM: Three-dimensional structures of alpha and beta protein with multiple calcium-binding sites and homologies with several different
chemokines. FASEB J 9(1):57–62, 1995. proteins. J Cell Biol 103(5):1635–1648, 1986.
348. Cowan SW, et al: Binding of heparin to human platelet factor 4. Biochem J 234(2): 382. Mosher DF, Doyle MJ, Jaffe EA: Synthesis and secretion of thrombospondin by cul-
485–488, 1986. tured human endothelial cells. J Cell Biol 93(2):343–348, 1982.
349. Visentin GP, et al: Antibodies from patients with heparin-induced thrombocytopenia/ 383. Schwartz BS: Monocyte synthesis of thrombospondin. The role of platelets. J Biol
thrombosis are specific for platelet factor 4 complexed with heparin or bound to endo- Chem 264(13):7512–7517, 1989.
thelial cells. J Clin Invest 93(1):81–88, 1994. 384. Aiken ML, et al: Effects of OKM5, a monoclonal antibody to glycoprotein IV, on plate-
350. Warkentin TE, Heparin-induced thrombocytopenia. Curr Hematol Rep 1(1):63–72, let aggregation and thrombospondin surface expression. Blood 76(12):2501–2509,
2002. 1990.
351. Rucinski B, et al: Uptake and processing of human platelet factor 4 by hepatocytes. 385. Asch AS, et al: Analysis of CD36 binding domains: Ligand specificity controlled by
Proc Soc Exp Biol Med 186(3):361–367, 1987. dephosphorylation of an ectodomain. Science 262(5138):1436–1440, 1993.
352. Deuel TF, et al: Platelet factor 4 is chemotactic for neutrophils and monocytes. Proc 386. Chung J, Gao AG, Frazier WA: Thrombospondin acts via integrin-associated protein
Natl Acad Sci U S A 78(7):4584–4587, 1981. to activate the platelet integrin alphaIIbbeta3. J Biol Chem 272(23):14740–14746,
353. Maione TE, et al: Inhibition of angiogenesis by recombinant human platelet factor-4 1997.
and related peptides. Science 247(4938):77–79, 1990. 387. Chung J, et al: Thrombospondin-1 acts via IAP/CD47 to synergize with collagen in
354. Brindley LL, Sweet JM, Goetzl EJ: Stimulation of histamine release from human alpha2beta1-mediated platelet activation. Blood 94(2):642–648, 1999.
basophils by human platelet factor 4. J Clin Invest 72(4):1218–1223, 1983. 388. Jurk K, et al: Thrombospondin-1 mediates platelet adhesion at high shear via gly-
355. Gewirtz AM, et al: Inhibition of human megakaryocytopoiesis in vitro by plate- coprotein Ib (GPIb): An alternative/backup mechanism to von Willebrand factor.
let factor 4 (PF4) and a synthetic COOH-terminal PF4 peptide. J Clin Invest 83(5): FASEB J 17(11):1490–1492, 2003.
1477–1486, 1989. 389. Lawler J, Hynes RO: An integrin receptor on normal and thrombasthenic platelets
356. Han ZC, et al: Platelet factor 4 inhibits human megakaryocytopoiesis in vitro. Blood that binds thrombospondin. Blood 74(6):2022–2027, 1989.
75(6):1234–1239, 1990. 390. Plow EF, et al: Related binding mechanisms for fibrinogen, fibronectin, von
357. Lambert MP, et al: Platelet factor 4 is a negative autocrine in vivo regulator of megakary- Willebrand factor, and thrombospondin on thrombin-stimulated human platelets.
opoiesis: Clinical and therapeutic implications. Blood 110(4):1153–1160, 2007. Blood 66(3):724–727, 1985.
358. Katz IR, et al: Protease-induced immunoregulatory activity of platelet factor 4. Proc 391. Gao AG, et al: Integrin-associated protein is a receptor for the C-terminal domain of
Natl Acad Sci U S A 83(10):3491–3495, 1986. thrombospondin. J Biol Chem 271(1):21–24, 1996.
359. Beyth RJ, Culp LA: Complementary adhesive responses of human skin fibroblasts to 392. Lawler J, Hynes RO: The structure of human thrombospondin, an adhesive glycopro-
the cell-binding domain of fibronectin and the heparan sulfate-binding protein, plate- tein with multiple calcium binding sites and homologies with several different pro-
let factor-4. Exp Cell Res 155(2):537–548, 1984. teins. J Cell Biol 103:1635–1648, 1986.

Kaushansky_chapter 112_p1829-1914.indd 1891 17/09/15 3:30 pm